Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Antisense Oligonucleotides Targeting Lipoprotein(a)

Research output: Contribution to journalReviewResearchpeer-review

  1. Coronary Microvascular Dysfunction: A Practical Approach to Diagnosis and Management

    Research output: Contribution to journalReviewResearchpeer-review

  2. Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy

    Research output: Contribution to journalReviewResearchpeer-review

  3. Peripheral Arterial Disease in Women: an Overview of Risk Factor Profile, Clinical Features, and Outcomes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Non-invasive imaging for subclinical coronary atherosclerosis in patients with peripheral artery disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Peripheral artery disease (PAD) screening in the asymptomatic population: why, how, and who?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Chronic lymphocytic leukaemia clones are detectable decades before diagnosis

    Research output: Contribution to journalLetterResearchpeer-review

  2. Lipoprotein(a) levels at birth and in early childhood: The COMPARE Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Long-term benefits and harms associated with genetic cholesteryl ester transfer protein deficiency in the general population

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk

    Research output: Chapter in Book/Report/Conference proceedingBook chapterCommunication

  5. A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE OF REVIEW: High lipoprotein(a) levels are observationally and causally, from human genetics, associated with increased risk of cardiovascular disease including myocardial infarction and aortic valve stenosis. The European Atherosclerosis Society recommends screening for elevated lipoprotein(a) levels in high-risk patients. Different therapies have been suggested and some are used to treat elevated lipoprotein(a) levels such as niacin, PCSK9 inhibitors, and CETP inhibitors; however, to date, no randomized controlled trial has demonstrated that lowering of lipoprotein(a) leads to lower risk of cardiovascular disease.

RECENT FINDINGS: Synthetic oligonucleotides can be used to inactivate genes involved in disease processes. To lower lipoprotein(a), two antisense oligonucleotides have been developed, one targeting apolipoprotein B and one targeting apolipoprotein(a). Mipomersen is an antisense oligonucleotide targeting apolipoprotein B and thereby reducing levels of all apolipoprotein B containing lipoproteins in the circulation. Mipomersen has been shown to lower lipoprotein(a) by 20-50% in phase 3 studies. AKCEA-APO(a)-LRx is the most recent antisense oligonucleotide targeting apolipoprotein(a) and thereby uniquely targeting lipoprotein(a). It has been tested in a phase 2 study and has shown to lower lipoprotein(a) levels by 50-80%. The treatment of elevated lipoprotein(a) levels with the newest antisense oligonucleotides seems promising; however, no improvement in cardiovascular disease risk has yet been shown. However, a phase 3 study of AKCEA-APO(a)-LRx is being planned with cardiovascular disease as outcome, and results are awaited with great anticipation.

Original languageEnglish
JournalCurrent Atherosclerosis Reports
Volume21
Issue number8
Pages (from-to)30
ISSN1523-3804
DOIs
Publication statusPublished - 20 May 2019

ID: 59306722